Navigation Links
1 disease, 2 mechanisms
Date:2/11/2013

While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, in collaboration with several other research teams in Germany*, have discovered that such early-onset prostate cancers are triggered by a different mechanism from that which causes the disease at a later age. Their findings are published today in Cancer Cell, and might have important consequences for the diagnosis and treatment of prostate cancer in younger patients.

The researchers compared the genomes of 11 early-onset tumours with 7 late-onset tumours and observed marked differences at the molecular level. The genomes of early-onset prostate tumours undergo a relatively small number of changes compared to tumours that develop in older patients.

However, this small number of events leads to crucial exchanges of DNA between chromosomes, causing genes that are normally independent to become tightly linked (known as 'fusion genes'). Many of the genes affected by these rearrangements are usually activated by androgen hormones, such as testosterone. Through these rearrangements they become connected to cancer genes, resulting in fusion genes that can be activated by androgen hormones, so that otherwise inactive genes with the potential to cause cancer are now switched on.

"Prostate cancer in young patients appears to be specifically triggered by androgens and to involve genetic alterations that distinguish this cancer from prostate tumours in older patients," explains Jan Korbel, who led the study at EMBL. "We also measured the levels of androgen receptors in a large cohort of patients from Hamburg, and found data consistent with our initial genomic analysis."

Younger patients with prostate cancer tend to have higher levels of androgen hormone receptors than older patients with the same disease. This could be a natural effect, because the level of these hormones decreases in men older than 50. But it supports the researchers' conclusion that androgens might trigger the mechanism leading to prostate cancer in younger patients, and not in older ones.

Further research is needed to provide the scientific and medical community with more details, particularly regarding the medical impact of testosterone levels in men. However, in the future these findings may have widespread clinical consequences. "We hope that our findings on the cause of the disease will promote the development of new strategies to diagnose, prevent, and even individually treat this cancer," explains Thorsten Schlomm from the Martini Klinik at the University Medical Center Hamburg-Eppendorf (UKE).


'/>"/>
Contact: Isabelle Kling
isabelle.kling@embl.de
49-622-138-78355
European Molecular Biology Laboratory
Source:Eurekalert

Related biology news :

1. Geneticist develops tool to identify genes important in disease, tailoring individual treatment
2. Obesity is major contributor to heart disease, impediment to diagnosis and treatment
3. USDA grant advancing deadly plant disease, insect research
4. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
5. UF receives $1 million from Keck Foundation to study mechanisms of inherited disease
6. Discovery of mechanisms predicting response to new treatments in colon cancer
7. Symposium: Protein-Folding Diseases: Models & Mechanisms
8. Force of nature: Defining the mechanical mechanisms in living cells
9. Researchers identify mechanisms that allow embryonic stem cells to become any cell in the human body
10. Mechanisms for a beneficial effect of moderate alcohol consumption on osteoporosis in women
11. X-rays reveal the self-defence mechanisms of bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/12/2016)... CLEVELAND , Dec. 12, 2016  Researchers ... commercial possibilities for graphene by combining the material ... a highly sensitive pressure detector able to sense ... of a small spider.  The ... and can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/14/2017)... ... 14, 2017 , ... Seattle-based Phase Genomics has announced the ... researchers around the globe. Long considered a “holy grail” in biological research, ... of scientific questions. The announcement was made today at the Plant & ...
(Date:1/13/2017)... ... January 13, 2017 , ... Two Kalamazoo entrepreneurs ... called fulvic acid that farms, greenhouses and hydroponics operations use to increase yields ... the fastest growing segments of customers using this high grade fulvic acid extracted ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit ... – a process that evaluates the patent estate of a company, its impact and ... a biomedical firm leading the way in technologies that transform energy sources such as ...
(Date:1/12/2017)... January 12, 2017 The Energy ... biggest facility for producing mycorrhizae. The Centre for Mycorrhizal ... potential of mycorrhizae and developed a technology that eventually ... ... The TERI facility has a production ...
Breaking Biology Technology: